3Ma YL, He QY. The clinical application of six-minute walking test in chronic obstructive pulmonary disease. Zhong hua Jie He He Hu Xi Za Zhi ,2007,30:699-701.
4Nishimura K, Lzumi T,Tsukino M,et al. Dyspnea is better predictor of 5- year survival than airway obstructive in patients with COPD. Chest,2002, 121 : 1434-1440.
5Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol, 2008, 4: 1119-1129.
6Malerba M, Ponticiello A, Radaeli A,et al. Effect of twelve-months thera- py with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, muhicenter, placebo-controlled study ( the AMETHIST Trial). Pulm Pharmacol Ther,2004,17:27-34.
7Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic ob- structive pulmonary disease. Cochrane Database Syst Rev, 2010, 2 : CD001287.
2GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
3Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
4Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
7Cerveri I, Brusasco V. Revisited role for mucus hyperseeretion in the Pathogenesis of COPD [ J ]. Euro Respire Rev, 2010,19 : 109- 112.
8卫生部.慢性阻塞性肺疾病诊疗规范(2011年版),2011.
9Lu M, Yao W, ghong N, et al. Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China [ J ]. Respirology ,2010,15 : 1072-1078.
